Owing to its impressive ability to kill tumor cells, especially in combination with interferon-g (IFNg), tumor necrosis factor (TNF) is widely appreciated as being a potential systemic therapeutic for the treatment of cancer. On the other hand, owing to its proinflammatory activities, administration of TNF leads to many systemic side effects and eventually to a potentially lethal systemic inflammatory response syndrome (SIRS). However, systemic treatment of tumor-bearing mice with TNF/IFNg in combination with BB-94 (a broad-spectrum metalloproteinase inhibitor) confers protection against TNF/IFNg-induced mortality, whereas preserving the antitumor activity. In this study, we investigated the effect of the adenoviral delivery of human tissue inhibitors of matrix metalloproteinase (hTIMP)-1 and hTIMP-2 genes on the outcome of TNF/IFNg antitumor therapy. The dose of adenovirus was limited to 10 8 PFU per mouse owing to the additive toxicity of combining it with TNF/IFNg therapy. Nevertheless, this dose was sufficient to achieve highly efficient adenoviral transfer and expression of hTIMP-1 and hTIMP-2 in the liver, but not the tumor. Treatment with this low dose of AdhTIMP-1 or AdhTIMP-2 was not enough to protect the host against the toxic effects of TNF/IFNg. However, it was sufficient to show a synergistic effect of hTIMPs with TNF/IFNg such that tumors regressed significantly faster. Interestingly, only AdTIMP-2 was able to prevent relapses after treatment.
Introduction
Tumor necrosis factor (TNF), a pleiotropic cytokine produced by activated monocytes and macrophages, can kill tumors, especially when combined with interferon-g (IFNg). 1, 2 However, its proinflammatory activities can provoke a potentially lethal systemic inflammatory response syndrome (SIRS) characterized by hypotension and severe hepatitis. 3, 4 Consequently, the use of TNF as an antitumor drug is limited to locoregional treatments. 5, 6 Our research is focused on the development of a safer systemic antitumor therapy based on TNF and IFNg.
During the last decade many reports have pointed out a crucial role for matrix metalloproteinases (MMPs) in all stages of tumor development and metastasis. MMPs constitute a family of zinc-and calcium-dependent proteases that can degrade the extracellular matrix (ECM) and basement membrane. Our laboratory has shown, using the broad-spectrum MMP inhibitor (MMPI) BB-94, that MMPs also play a mediating role in TNF-induced hepatitis. Furthermore, systemic treatment of tumor-bearing mice with TNF/IFNg in combination with BB-94 confers protection against the lethal effects of TNF/IFNg, whereas preserving the antitumor activity. 7 This indicates that MMPIs might be effective for increasing the therapeutic potential of systemic TNF/IFNg antitumor therapy.
In accordance with this hypothesis, we investigated possible protective roles for the naturally occurring tissue inhibitors of MMPs (TIMPs) in TNF/IFNg therapy. TIMPs, of which four are known (TIMP-1-4), are the major endogenous regulators of MMP activities in the tissues. [8] [9] [10] [11] [12] In our model system, we tested hTIMP-1 and hTIMP-2 by adenoviral delivery and by high-pressure injection of plasmids expressing hTIMP-1 or hTIMP-2. TIMP-2 is the only TIMP known to inhibit active forms of almost all known MMPs. At lower concentrations, TIMP-2 participates in the activation of proMMP-2 by MT1-MMP, whereas high concentrations of TIMP-2 completely block the activities of both MMP-2 and MT1-MMP. On the other hand, TIMP-1 is a poor inhibitor of MMP-19 and some MT-MMPs, preferentially associating with pro-MMP-9. 13 TIMPs have a pronounced antitumor potential, first observed with recombinant TIMP [14] [15] [16] and later with tumor cells engineered to overexpress TIMPs. [17] [18] [19] [20] [21] Recent data have shown that in vivo gene therapy with TIMPs is an excellent treatment for established primary tumors, at least in small animal models, [22] [23] [24] [25] [26] [27] and also protects normal, non-cancerous target tissue against metastases. 28, 29 The primary aim of this research was to examine the effects of constitutive expression of TIMP gene products on the outcome of antitumor therapy with TNF/IFNg. Replication-defective adenoviral vectors were used to achieve gene transfer. We show that a dose of only 10 8 PFU of AdhTIMP-1 or AdhTIMP-2 is sufficient to obtain a synergistic effect with a TNF/IFNg therapy. Despite this, no protective effect of the adenoviruses against TNF/IFNg induced toxicity was observed and only AdhTIMP-2 could significantly prevent relapse of the tumors after the treatment.
Materials and methods

Production of adenoviruses and expression vectors
Construction of AdhTIMP-1 and AdhTIMP-2 has been described before. 30 The hTIMP-1 expression vector, used for the injection of naked plasmids, was constructed by cloning hTIMP-1 complementary DNA (cDNA) in the pCAGGS expression vector, which contains the chicken b-actin/rabbit b-globin hybrid promoter (AG), the enhancer of the human cytomegalovirus immediate early promoter, and the gene conferring ampicillin resistance. Plasmid DNA was prepared using a commercial kit (Qiagen, Venlo, Netherlands).
Cell lines, cell culture and DNA transfection
The murine B16BL6 melanoma cell line was a gift from Dr M Mareel (Ghent, Belgium) by courtesy of Dr I Fidler (Dallas, USA). The BWTG3 cell line was provided by Dr C Szpirer (Brussels, Belgium). B16BL6 and BWTG3 cells were grown at 371C in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 1% Na pyruvate, 1% D-glutamine, 100 U/ml penicillin and100 mg/ml streptomycin.
Exponentially growing B16BL6 and BWTG3 cells (3 Â 10 5 ) were seeded in 2 ml of medium in a 3.5 cm plate and incubated overnight. The following day, cells were infected with AdRR5, AdhTIMP-1 or AdhTIMP-2 in 0.5 ml serum-free medium for 2 h at multiplicities of infection (MOI) 100. After 24 h, conditioned medium was collected and total RNA was isolated.
Semiquantitative RT-PCR Total RNA was extracted from cell cultures with 1 ml Trizol (Invitrogen NV, Belgium) following the manufacturer's instructions. Liver and tumor samples were homogenized in Trizol, and total RNA was extracted. Detecting the secretion of TIMP-1 and TIMP-2 by reversed gelatin zymography Functional TIMP-1 and TIMP-2 in the conditioned medium of AdTIMP-1 and AdTIMP-2-infected cells was determined by reverse zymography. Samples (20 ml) were loaded on 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels co-polymerized with gelatin (1 mg/ ml) and 4-aminophenylmercuric acetate-activated proMMP-2. After electrophoresis, SDS was removed by incubation for 20 min in 2.5% Triton X-100. The gel was then incubated at 371C for 24 h in 50 mM Tris-HCl (pH 7.7), 0.15 M NaCl, 10 mM CaCl 2 , 0.05% Brij-35 and 0.02% NaN 3 . Gels were stained with 1% Coomassie Brilliant Blue (Sigma, Bornem, Belgium); bands of gelatinase inhibitory activity representing TIMPs appeared dark against the partially digested background of gelatin.
ELISA quantification of human TIMP-1 and human TIMP-2 in mouse sera Adenoviruses were injected into the tail vein of mice in a volume of 200 ml. At various time points, blood was drawn from the tail, allowed to coagulate, centrifuged for 5 min at 14 000 Â g and serum was collected. Human TIMP-1 and human TIMP-2 were quantified by enzymelinked immunosorbent assay (ELISA) according to the manufacturer's instructions (R&D Bioscience, Abingdon, UK).
In vivo tumor experiments
All animals used for in vivo experiments were female C57BL/6Jico mice (Iffa Credo Ico, France). They were kept in a conventional animal house and all procedures were carried out according to the guidelines of the animal ethics committee of the faculty of sciences at Ghent University (Ghent, Belgium). Recombinant murine TNF (1.0 Â 10 9 IU/mg) and murine IFNg (1.1 Â 10 9 IU/mg) were produced in Escherichia coli and purified in-house (lipopolysaccharide content not detectable in Limulus Amebocyte lysate assay).
Tumor experiments were performed by s.c. inoculation of 6 Â 10 5 B16BL6 melanoma cells, suspended in 0.1 phosphate-buffered saline (PBS), in the shaved left thigh of mice on day 0. All adenoviruses were prepared as aliquots of 1 Â 10 8 PFU in 0.2 ml of PBS and 10% glycerol, and injected i.v. 7 days after inoculation of the tumor.
Tumor growth was monitored from day 10 to day 20. Antitumor experiments were started 10 days after the inoculation of the tumor. Mice were daily injected close to the tumor with 10 mg TNF þ 5000 U IFNg for 10 consecutive days. Tumor size was determined daily as the product of the major and minor diameters (mm 2 ).
Statistical analysis
Percentages of tumor-free mice were compared using an unpaired Student's t-test with Welch's correction. Statistical significance was defined as Po0.05.
Results
The maximal tolerated dose of adenovirus in combination with TNF is 10 8 PFU Owing to the proinflammatory activities of TNF, its administration induces inflammation and eventually a potentially lethal SIRS. To investigate a possible protective role for TIMPs during TNF/IFNg therapy, we used an adenoviral delivery system to overexpress and deliver hTIMP-1 and hTIMP-2. But marked inflammation is also induced by injection of adenoviral application. Therefore, we determined the maximal dose of adenovirus combined with TNF that mice can resist.
We investigated whether adenoviral delivery influences the survival of female C57/BL6 mice in the in vivo bolus TNF model. Groups of three mice were each given different doses (10 Expression of hTIMP-1 and hTIMP-2 is much higher in mouse liver cells than in B16BL6 melanoma cells both in vitro and in vivo Expression of hTIMP-1 and hTIMP-2 was evaluated in vitro after adenoviral gene transfer. Infection of BWTG3 mouse hepatoma cells and B16BL6 melanoma cells with AdhTIMP-1 or AdhTIMP-2 had no effect on cell survival in comparison to infection with AdRR5 (data not shown).
Conditioned medium was collected 24 h after infection. RT-PCR on isolated RNA showed that both infected cell lines expressed hTIMP-1 and hTIMP-2 mRNA. However, the expression of hTIMP-1 and hTIMP-2 was much higher in the mouse hepatoma cell line than in the B16BL6 melanoma cell line. As expected, neither hTIMP-1 nor hTIMP-2 was expressed after infection with AdRR5 ( Figure 1a) . To visualize the presence of intrinsic gelatinolytic activity produced by infected BWTG3 and B16BL6 cells, serum-free conditioned medium was collected and tested by in vitro reverse zymography ( Figure 1b) . As expected, bands of MMP inhibitory activity representing TIMP-1 and TIMP-2 were detected in the supernatants of BWTG3 cells infected with AdhTIMP-1 and AdhTIMP-2, respectively, but not in the supernatants of AdRR5-infected cells. Furthermore, TIMPs were not detected in the supernatants of infected B16BL6 cells, again showing that the cells originating from the liver are infected more efficiently than the melanoma cells.
Mouse liver is highly susceptible to transduction by adenoviruses, even when vectors are delivered systemically. 28, 31 To verify this, we evaluated the adenovirusmediated hTIMP-1 and hTIMP-2 gene transfer into mouse livers by injecting B16BL6 tumor-bearing mice (n ¼ 2) i.v. with AdhTIMP-1 or AdhTIMP-2. Three days later, livers and tumors were removed and RNA was isolated. RT-PCR for hTIMP-1 and hTIMP-2 demonstrated that the liver expressed the hTIMPs after systemic injection of the adenoviruses, but the tumor did not (Figure 1c) . Moreover, no hTIMP expression was detected in the tumor even after intratumoral injection of the viruses (data not shown). These data demonstrate highly efficient adenoviral transfer to the liver, but not to the tumor, and consequent expression of hTIMP-1 and hTIMP-2.
hTIMP expression from adenoviruses persists longer than after high pressure injection of hTIMP-expressing pCAGGS-plasmids To determine whether TIMPs are secreted into the serum in vivo, we measured the levels of hTIMP-1 and hTIMP-2 by ELISA at different time points after systemic administration of 10 8 PFU AdhTIMP-1 or AdhTIMP-2. No hTIMP protein was detected in the serum of uninfected controls, but administration of hTIMP-expressing adenoviruses led to highly elevated serum levels (Figure 2 ), even though a very low adenoviral dose was used. Adenoviral expression increased during the first days, reaching a peak 3-7 days after the injection, and then decreased to just above the detection threshold of 0.011 ng/ml 2 weeks after virus application.
It has been demonstrated that rapid injection of a large volume of plasmid DNA solution into the tail vein of mice results in the expression of large amounts of the transgene product in the liver. [32] [33] [34] We used this method to administer 100 mg of plasmids encoding hTIMP-1, and observed that serum levels peaked after 24 h, but was barely detectable at 48 h. Although peak serum levels after hydrodynamic delivery was higher than after adenoviral delivery, we chose the latter method because it resulted in a much more durable expression.
Use of hTIMP-expressing adenoviruses improves the safety of a TNF/IFNg antitumor therapy Because the establishment of tumors requires efficient MMP mediated invasion and angiogenesis, we first evaluated the effects of hTIMP-1 and hTIMP-2 overexpression on tumor growth. Seven days after inoculation of a B16BL6 tumor, the mice were injected into the tail vein with one of the viruses, and tumor growth was monitored for 13 days. The tumor growth rates of the control groups (non-treated mice and mice treated with AdRR5) were not significantly different from those of the AdhTIMP-pretreated groups (Figure 3a) .
Still, the primary aim of this research was to examine the effect of constitutive expression of hTIMP gene products on the outcome of a TNF/IFNg-based antitumor therapy. Therefore, tumors were again generated by subcutaneous (s.c.) inoculation of B16BL6 melanoma cells, and 7 days later the adenoviruses (AdhTIMP-1, AdhTIMP-2 and AdRR5 as control) were administered at 10 8 PFU per mouse. Starting 3 days after viral infection, the mice were treated daily for 10 days with 10 mg TNF combined with 5000 U IFNg (Figure 3b ). This resulted in the death of 20-30% of the mice in each group, but no statistically significant differences in final mortality rates between the three groups were observed (Table 1) . However, tumors of AdhTIMP-pretreated animals regressed much faster (Figure 3c ) and all surviving animals pretreated with hTIMP became tumor free after daily Table 1 ).
After termination of the TNF/IFNg treatment, surviving tumor-bearing mice were killed but tumor-free mice were monitored for relapse of the tumor for another 20 days. A significant difference was seen between the AdhTIMP-2-pretreated animals and the other groups. Nearly 60% of control mice and AdhTIMP-1-pretreated mice that where tumor free at the end of the therapy regained a solid tumor within 20 days. Relapse was significantly lower in mice pretreated with AdhTIMP-2 (P ¼ 0.02 and 0.01, as compared to control and hTIMP-1-pretreated mice, respectively; Table 1 ).
We also studied the antitumor effect of hTIMP-1 and hTIMP-2 after a single intratumoral injection of the respective adenoviruses. When palpable tumors appeared, 10 8 PFU of AdhTIMP-1, AdhTIMP-2 or AdRR5 were injected directly into the tumors. As expected from the intratumoral expression studies, this did not enhance the antitumor effects of TNF/IFNg (data not shown).
In conclusion, treatment with only 10 8 PFU of AdhTIMP-1 or AdhTIMP-2 is sufficient to synergize with TNF/IFNg therapy, but only AdTIMP-2 could prevent relapse after treatment.
Discussion
TNF was originally identified through its capacity to selectively kill tumor cells by necrosis and apoptosis both in vitro and in vivo, but attempts to use it in systemic anticancer therapy have failed owing to severe side effects generated by even subtherapeutic doses. We have recently shown that the broad-spectrum MMPI BB-94, when incorporated in systemic TNF/IFNg therapy, prevented mortality in tumor-bearing mice without interfering with the antitumor activity of TNF/IFNg. This points to the possibility of using MMPIs to boost the therapeutic potential of systemic TNF/IFNg antitumor therapy. However, the use of synthetic, low-molecular weight MMPIs (BB94, Marimastat, MM1270) to treat cancer patients was associated with some undesirable systemic side effects in recent clinical trials. 35 Therefore, we wanted to determine if inhibiting MMPs by TIMPs could also be protective during TNF/IFNg treatment.
This study evaluated the synergism of a low dose of AdhTIMP-1 or AdhTIMP-2 with TNF/IFNg. We evaluated protection of the host and affects on growth, regression and relapse of the tumor. Treatment with only 10 8 PFU of AdhTIMP-1 or AdhTIMP-2 was not enough to protect against the toxic effects of TNF/IFNg. However, this low dose was sufficient for synergy between the hTIMP and TNF/IFNg during regression of the tumor, but only AdTIMP-2 could significantly prevent relapse after treatment.
First, we found that we should not exceed an adenovirus dose of 10 8 PFU per mouse owing to the combined toxicity of the virus and TNF. Brand et al. 28 have shown that 3 Â 10 10 and 6 Â 10 10 PFU were necessary for transduction of 50 and 100% of hepatocytes, respectively, as determined by X-gal staining 3 days after delivery of Adbgal, whereas 0.75 Â 10 10 PFU resulted in infection of o10% of hepatocytes in vivo. However, we showed by RT-PCR and ELISA that a 100-fold lower dose (10 8 PFU) was sufficient to express hTIMP-1 and hTIMP-2 and to secrete them in the serum.
We also demonstrated in vitro (RT-PCR and reverse zymography) as well as in vivo that adenoviral infection and consequent expression of hTIMP-1 and hTIMP-2 is efficient in liver cells but not in tumor cells and that hTIMP proteins are secreted in the serum of mice. Mouse liver has been shown to be highly susceptible to transduction by adenoviruses, even after systemic delivery of the vectors. 28, 31 As TIMPs are secreted proteins, they could have a profound bystander effect on cells that are not transduced by the gene delivery vector. As was demonstrated before, i.v. delivery of gene therapy vectors could lead to secretion and diffusion of the anti-invasive or anti-angiogenic gene products, which could effectively suppress s.c. tumor growth, showing that it is not necessary to deliver and express therapeutic genes in tumor cells. 26, 36, 37 We also tested the expression and secretion of hTIMP-1 and hTIMP-2 using a hydrodynamics-based plasmid transfection method. This procedure involves rapid 32 , and higher peak expression levels in the serum compared to the adenoviral delivery method. However, adenoviral delivery resulted in a much longer duration of expression. It might be possible to extend the duration of expression following hydrodynamic delivery by repeating the injections during the 10 days of TNF/ IFNg therapy, but this is not a practicable solution. Consequently, the adenoviral delivery method became our default choice.
The antitumoral potential of TIMPs was first observed in tumor cells engineered in vitro to overexpress TIMPs. [17] [18] [19] [20] [21] With the adenoviral dose we used we could not observe any tumorstatic effect in the in vivo tumor model. The adenoviral doses reported in the literature on in vivo TIMP gene therapy are higher 25, 26, 28 than the dose we used, and resulted in higher hTIMP serum levels. 28 Adenoviruses have also been delivered directly into the tumor 24, 27 or into normal, non-cancerous tissue to protect it against metastasis. 28 The main purpose of the study was to investigate whether constitutive expression of hTIMP gene products affected the outcome of TNF/IFNg antitumor therapy. Although we had observed before that the broadspectrum MMPI BB-94 can protect mice against the toxic side effects of TNF/IFNg therapy, we could not see any difference in the survival rates of the hTIMPpretreated animals during the treatment compared to the control animals. Nevertheless, we noticed that all surviving hTIMP-pretreated animals became tumor free after daily injection with this low dose of TNF/IFNg, whereas some of the control animals still had measurable tumors. Furthermore, only AdhTIMP-2-pretreated mice were protected against relapse of the tumor within 20 days after completion of the treatment. The pronounced protection against regrowth of the tumor in the hTIMP-2-pretreated group, 2-4 weeks after virus application, was somewhat surprising because serum hTIMP-2 levels had already declined 200-fold by the time the treatment was completed. Therefore, we should look for the differences between hTIMP-1 and hTIMP-2-pretreated groups both during and after the treatment.
MMPs are involved in a wide range of phenomena associated with tumor progression. The molecular mechanisms by which hTIMP-2 or hTIMP-1 synergizes with TNF/IFNg might involve the direct inhibition of tumor cell growth, tumor invasion or angiogenesis, because hTIMP-1 and hTIMP-2 can affect all of these tumor stages. 38 The difference in the inhibitory characteristics of the two TIMPs might explain why hTIMP-2 exerts a stronger synergistic effect than hTIMP-1. TIMP-1 inhibits most MMPs but is only a weak inhibitor of MMP-19 and MT-MMPs, but TIMP-2 can inhibit active forms of almost all MMPs identified to date. We have seen that during TNF/IFNg treatment the expression of MMP-14 (MT1-MMP) and MMP-16 (MT3-MMP) is downregulated in the tumor (data not shown). MT-MMPs have a well-known function in promoting cell migration, invasion, experimental metastasis and angiogenesis. 39 Therefore, it is not surprising that one of the tumor destructive functions of TNF/IFNg could be downregulation of two of the most important membrane associated MMPs. Unlike TIMP-1, TIMP-2 is a strong inhibitor of MMP-14 and MMP-16 and therefore could thus help TNF/IFNg in inhibiting those two MT-MMPs and in destroying the tumor and preventing it to relapse. In addition, a growing body of evidence indicates that TIMP-2 may induce an antitumor effect beyond the inhibition of MMP enzymatic activity by affecting angiogenesis directly. [40] [41] [42] This, to our knowledge, has not been described for TIMP-1. This MMP-independent inhibition of angiogenesis could also be a reason why TIMP-2, in contrast to TIMP-1, can inhibit the regrowth of TNF/IFNg-treated tumors.
Clearly, further investigations are required to answer the question of the TIMP-2-specific effect, and to make a more informed choice of TIMPs. In fact, TIMP-4 is also upregulated in the tumor during TNF/IFNg therapy (data not shown). Therefore, it could be interesting to combine TNF/IFNg treatment with TIMP-4 gene therapy. This might mimic part of the destructive functions of TNF/ IFNg and may permit further decreases in the TNF/IFNg dose.
The short-lived transgene expression by first generation adenoviral vectors and their acute toxicity, especially when combined with TNF/IFNg, indicates that they are not the best choice. Therefore, we are investigating the use of adeno-associated viruses, which do not induce inflammation and whose incorporation in the genome leads to a much more durable expression of the transgene. 43 Adenovirus-mediated gene transfer to tumor cells could also be an option. An intravenously administered vector that specifically delivers transgene products to tumors could raise the tumor/liver ratio of the transgene and increase its local expression. 44, 45 The use of MMPIs in clinical trials has been disappointing and there are several potential reasons for this. 13, 35, 38 First, some MMPIs can cause serious side effects. The rational design and evaluation of more selective synthetic inhibitors may be one route to overcome this problem. The use of hTIMPs by gene transfer is another possibility. Our data demonstrate that such gene-based therapy does not cause any toxicity in mice and that gene therapy using TIMPs may have a broad clinical potential. Moreover, inhibitory proteins may have a better pharmacokinetic profile as well as inhibitory power than small drugs. However, small chemical compounds may have a better penetrance into tumors. We believe that gene therapy with TIMPs certainly has a future, provided better vectors become available and specific targeting of the tumor cells becomes possible. Secondly, most of the MMPIs have been tested as a single agent without the combination with conventional chemotherapy or radiotherapy. As many MMPIs act as cytostatic drugs, they may not be effective to control tumor growth and progression. The use of MMPIs or TIMPs in combination therapy, for example with TNF/IFNg, could be a good solution. Thirdly, some MMPs might limit tumor growth and metastasis through local production (by processing members of the ECM) of angiogenesis-suppressing molecules such as angiostatin, tumstatin and endostatin or other factors that have negative effects on tumor growth. 13, 38 In conclusion, the combined results in this study show that incorporating hTIMP genes in TNF/IFNg therapy, and especially hTIMP-2, could be a judicious choice.
